FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003446750> ?p ?o ?g. }

• W2003446750 endingPage "444" @default.
• W2003446750 startingPage "437" @default.
• W2003446750 abstract "The optimal therapeutic approach for patients with Hodgkin's disease (HD) and human immunodeficiency virus (HIV) infection is unknown. In an attempt to improve the results obtained with standard chemotherapy and to decrease the occurrence of opportunistic infections (OI) during chemotherapy and follow-up observed in a previous experience, the authors designed a prospective combined antineoplastic and antiretroviral approach.Between March 1989 and March 1992, 17 consecutive previously untreated patients (median age, 30 years) with HD and HIV infection were enrolled. They had Stage III and IV or Stage I and II disease with adverse prognostic factors. The median CD4+ cell count was 184/microliters. Patients were stratified in two groups and treated accordingly. Group A was made up of patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than 3 and without OI. These patients received epirubicin 70 mg/m2 intravenously on day 1, bleomycin 10 mg/m2 IV on day 1, and vinblastine 6 mg/m2 IV on day 1 (regimen EBV). Group B was made up of patients with PS of 3 or greater or previous OI who had received a 50% reduced dose of epirubicin and vinblastine and a full dose of bleomycin. Courses were repeated every 21 days for six cycles. Zidovudine was given at the dose of 500 mg/day from the beginning of chemotherapy in Group B and after the third cycle in Group A.Overall, 14 of 17 (82%) patients had an objective response and 9 of 17 (53%) achieved a complete remission (CR) of disease for a median duration of 20 months. Toxicity was moderate with Grade 3-4 leukopenia in eight patients and Grade 3 thrombocytopenia in one patient. Thirteen of 17 patients received zidovudine as planned with a median duration of 9 months. Only one patient had OI during or after chemotherapy (median follow-up, 11 months). No worsening of HIV markers during the combined therapy was seen, with the median CD4+ cell count before and after therapy being 184/microliters and 203/microliters, respectively. The median survival time was 11 months, with an actuarial survival rate of 48% at 36 months. The median survival time for the nine patients with CR has not been reached at the time of this analysis.These results revealed the feasibility and the activity of the combination of EBV regimen and zidovudine. Objective response rate seems similar to those previously observed in patients receiving standard chemotherapy, but only one patient had OI, and this compares favorably with the 16 OI observed in 28 patients treated with standard chemotherapy (6% versus 57%) in the authors' previous experience. Thus, it seems that the addition of antiretroviral therapy to the EBV regimen decreased the occurrence of OI during chemotherapy or follow-up." @default.
• W2003446750 created "2016-06-24" @default.
• W2003446750 creator A5004282462 @default.
• W2003446750 creator A5015952023 @default.
• W2003446750 creator A5021793394 @default.
• W2003446750 creator A5034123305 @default.
• W2003446750 creator A5038699632 @default.
• W2003446750 creator A5045745778 @default.
• W2003446750 creator A5046311100 @default.
• W2003446750 creator A5051976240 @default.
• W2003446750 creator A5068719003 @default.
• W2003446750 creator A5070566745 @default.
• W2003446750 date "1994-01-15" @default.
• W2003446750 modified "2023-09-27" @default.
• W2003446750 title "Combined antineoplastic and antiretroviral therapy for patients with hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients" @default.
• W2003446750 cites W1967910701 @default.
• W2003446750 cites W1978622638 @default.
• W2003446750 cites W1987348395 @default.
• W2003446750 cites W2003385864 @default.
• W2003446750 cites W2043544753 @default.
• W2003446750 cites W2056333372 @default.
• W2003446750 cites W2068518657 @default.
• W2003446750 cites W2075232654 @default.
• W2003446750 cites W2089112499 @default.
• W2003446750 cites W2114139304 @default.
• W2003446750 cites W2130904233 @default.
• W2003446750 cites W2261080275 @default.
• W2003446750 cites W2395607120 @default.
• W2003446750 cites W4240794527 @default.
• W2003446750 cites W4243561702 @default.
• W2003446750 cites W4293241248 @default.
• W2003446750 doi "https://doi.org/10.1002/1097-0142(19940115)73:2<437::aid-cncr2820730232>3.0.co;2-2" @default.
• W2003446750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7507401" @default.
• W2003446750 hasPublicationYear "1994" @default.
• W2003446750 type Work @default.
• W2003446750 sameAs 2003446750 @default.
• W2003446750 citedByCount "65" @default.
• W2003446750 countsByYear W20034467502012 @default.
• W2003446750 countsByYear W20034467502013 @default.
• W2003446750 countsByYear W20034467502014 @default.
• W2003446750 countsByYear W20034467502015 @default.
• W2003446750 countsByYear W20034467502016 @default.
• W2003446750 countsByYear W20034467502017 @default.
• W2003446750 countsByYear W20034467502018 @default.
• W2003446750 countsByYear W20034467502020 @default.
• W2003446750 countsByYear W20034467502022 @default.
• W2003446750 crossrefType "journal-article" @default.
• W2003446750 hasAuthorship W2003446750A5004282462 @default.
• W2003446750 hasAuthorship W2003446750A5015952023 @default.
• W2003446750 hasAuthorship W2003446750A5021793394 @default.
• W2003446750 hasAuthorship W2003446750A5034123305 @default.
• W2003446750 hasAuthorship W2003446750A5038699632 @default.
• W2003446750 hasAuthorship W2003446750A5045745778 @default.
• W2003446750 hasAuthorship W2003446750A5046311100 @default.
• W2003446750 hasAuthorship W2003446750A5051976240 @default.
• W2003446750 hasAuthorship W2003446750A5068719003 @default.
• W2003446750 hasAuthorship W2003446750A5070566745 @default.
• W2003446750 hasBestOaLocation W20034467501 @default.
• W2003446750 hasConcept C121608353 @default.
• W2003446750 hasConcept C126322002 @default.
• W2003446750 hasConcept C141071460 @default.
• W2003446750 hasConcept C146357865 @default.
• W2003446750 hasConcept C151730666 @default.
• W2003446750 hasConcept C188816634 @default.
• W2003446750 hasConcept C197934379 @default.
• W2003446750 hasConcept C203014093 @default.
• W2003446750 hasConcept C2776232574 @default.
• W2003446750 hasConcept C2776694085 @default.
• W2003446750 hasConcept C2776755627 @default.
• W2003446750 hasConcept C2776802502 @default.
• W2003446750 hasConcept C2777132456 @default.
• W2003446750 hasConcept C2777447569 @default.
• W2003446750 hasConcept C2780216070 @default.
• W2003446750 hasConcept C2780727368 @default.
• W2003446750 hasConcept C2780835546 @default.
• W2003446750 hasConcept C2780866839 @default.
• W2003446750 hasConcept C2781413609 @default.
• W2003446750 hasConcept C3013748606 @default.
• W2003446750 hasConcept C530470458 @default.
• W2003446750 hasConcept C71924100 @default.
• W2003446750 hasConcept C86803240 @default.
• W2003446750 hasConcept C90924648 @default.
• W2003446750 hasConceptScore W2003446750C121608353 @default.
• W2003446750 hasConceptScore W2003446750C126322002 @default.
• W2003446750 hasConceptScore W2003446750C141071460 @default.
• W2003446750 hasConceptScore W2003446750C146357865 @default.
• W2003446750 hasConceptScore W2003446750C151730666 @default.
• W2003446750 hasConceptScore W2003446750C188816634 @default.
• W2003446750 hasConceptScore W2003446750C197934379 @default.
• W2003446750 hasConceptScore W2003446750C203014093 @default.
• W2003446750 hasConceptScore W2003446750C2776232574 @default.
• W2003446750 hasConceptScore W2003446750C2776694085 @default.
• W2003446750 hasConceptScore W2003446750C2776755627 @default.
• W2003446750 hasConceptScore W2003446750C2776802502 @default.
• W2003446750 hasConceptScore W2003446750C2777132456 @default.
• W2003446750 hasConceptScore W2003446750C2777447569 @default.
• W2003446750 hasConceptScore W2003446750C2780216070 @default.
• W2003446750 hasConceptScore W2003446750C2780727368 @default.

• next